Zoe Johnson

Campus Biotech Innovation Park
Geneve, GE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Journal: Cell reports

Published: May 19, 2026

IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy.

IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy.

Journal: Cell death discovery

Published: October 28, 2025

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Journal: Cell reports

Published: May 19, 2025

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Journal: Molecular cancer therapeutics

Published: August 10, 2023

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors.

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors.

Journal: Immuno-oncology technology

Published: May 26, 2023

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Journal: Cancer research communications

Published: November 22, 2022

Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial.

Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial.

Journal: Journal of pharmaceutical and biomedical analysis

Published: March 10, 2022

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.

Journal: Cell reports

Published: April 23, 2020

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Journal: Molecular cancer therapeutics

Published: November 07, 2017

Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System.

Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 01, 2017

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 05, 2016

Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.

Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.

Journal: The Journal of biological chemistry

Published: June 29, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026